摘要
目的观察肠复方治疗晚期大肠癌的临床疗效。方法选择晚期大肠癌患者60例,随机分为治疗组和对照组各30例,另选择健康体检者10人设为正常组。对照组给予对症支持治疗,治疗组在对照组基础上给予肠复方,每日1剂。两组均治疗并随访1年,计算患者半年及1年生存率。采集正常组外周血,治疗组及对照组治疗前及治疗2个月时采集外周血,采用荧光定量PCR检测外周血中细胞角蛋白20(CK 20)mRNA表达,并采用免疫吸附法检测端粒酶表达量;治疗2个月后通过CT检查评估瘤体控制率;治疗后观察疾病进展时间。结果治疗2个月后治疗组、对照组瘤体控制率分别为66.67%、26.67%,治疗组高于对照组(P=0.002)。治疗组及对照组患者外周血CK20 mRNA、端粒酶表达量显著高于正常组(P<0.01)。治疗组治疗2个月外周血CK20 mRNA、端粒酶表达较治疗前显著降低(P<0.01),对照组治疗2个月外周血CK20 mRNA、端粒酶表达较治疗前显著升高(P<0.01);治疗2个月治疗组外周血CK20 mRNA、端粒酶表达显著低于对照组(P<0.01)。治疗组疾病进展时间明显长于对照组(P<0.01)。治疗组1年期生存率明显高于对照组(P=0.022)。结论肠复方治疗晚期大肠癌有效,能提高瘤体控制率,延长疾病进展时间,提高远期生存获益,并降低患者外周血中端粒酶及CK20 mRNA表达。
Objective To observe the clinical efficacy cancer. Methods Sixty advanced colorectal cancer were of Changfufang （肠复方）） in treating advanced colorectal randomized into treatment group and control group with 30 patients in each group. Another 10 healthy people were set as the normal group. The control group was given symp- tomatic and supportive care, in addition to which the treatment group was administered Changfufang with one dose per day. The treatment and follow-up period was 1 year. After 1-year follow-up, half-year and one-year survival rates were calculated. The peripheral blood of the normal group was collected, peripheral blood of the treatment group and the control group before treatment as well as at the second month of treatment. Expression of peripheral cytokeratin 20 （CK20） mRNA was detected by fluorescence quantitative PCR and telomerase activity was detected by immunosorbent assay. At the end of the second month of treatment, the tumor control rate was evaluated by CT examination ; the time to progression was observed after treatment. Results After two months of treatment, the tumor control rates of the treatment group and the control group were 66.67% and 26.67%, respectively with significant difference （P = 0. 002）. The expressions of peripheral CK20 mRNA and telomerase in the treatment group were significantly higher than those in the control group （ P 〈 0. 01 ）. At the second month of treatment, the expressions of peripheral CK20 mRNA and telomerase in the treatment group decreased significantly （P 〈0.01 ）, while those in the control group in- creased significantly （P 〈 0. 01 ）, and those in the treatment group was significantly lower than those in the control group （P 〈 0.01 ）. The time to progression in the treatment group was significantly longer than that in the control group （P 〈0.01 ）. The one-year survival rate in the treatment group was significantly higher than that in the control group （P = 0. 022 ）. Conclusion Chanffufang seems to be effective in treating advanced colorectal cancer, it could improve the tumor control rate, prolong the time to progression, improve long-term survival benefit, and reduce the expressions of peripheral telomerase and CK20 mRNA.
出处
《中医杂志》
CSCD
北大核心
2017年第11期941-945,共5页
Journal of Traditional Chinese Medicine
基金
湖南省中医药管理局项目(2012140)
中南大学湘雅临床大数据系统建设项目(2013003)
关键词
晚期肠癌
肠复方
外周循环血
CK20MRNA
端粒酶
advanced colorectal cancer
Chanffufang （肠复方））
peripheral circulation
CK20 mRNA
telomerase
